Paragon Capital Management (Utah)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Paragon Capital Management (Utah)’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,944	Closed	-$1.65M	–	68
2024 Q3	$1.65M	Buy	4,944 +151	+3%	+$48K	1.22%	30
2024 Q2	$1.31M	Buy	+4,793	New	+$1.39M	1%	47
2024 Q1	–	Sell	-4,259	Closed	-$1.38M	–	71
2023 Q4	$1.38M	Buy	4,259 +1,147	+37%	+$360K	1.1%	37
2023 Q3	$1.12M	Buy	3,112 +191	+7%	+$73.7K	0.95%	45
2023 Q2	$1.11M	Buy	2,921 +153	+6%	+$62.3K	0.93%	47
2023 Q1	$1.33M	Sell	2,768 -263	-9%	-$123K	1.16%	28
2022 Q4	$1.27M	Buy	3,031 +699	+30%	+$282K	1.19%	20
2022 Q3	$973K	Buy	2,332 +25	+1%	+$12.5K	0.95%	37
2022 Q2	$1.14M	Buy	+2,307	New	+$1.2M	1.16%	24
2022 Q1	–	Sell	-1,930	Closed	-$1.46M	–	71
2021 Q4	$1.46M	Buy	+1,930	New	+$1.44M	1.25%	30

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Paragon Capital Management (Utah)'s BIO Position: Q4 2024 in Review

Paragon Capital Management (Utah) sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2024, closing a stake of 4,944 shares — an estimated $1.65M sold.

Paragon Capital Management (Utah) first reported a position in BIO in Q4 2021 and held it in 10 quarters. The position peaked at $1.65M in Q3 2024. 456 funds tracked by Wall St. Rank hold BIO as of Q4 2024.

Paragon Capital Management (Utah) reported no remaining Bio-Rad Laboratories Class A position as of Q4 2024 after selling out during the quarter.
Paragon Capital Management (Utah) sold 4,944 Bio-Rad Laboratories Class A shares in Q4 2024, an estimated $1.65M.
Paragon Capital Management (Utah) first reported a position in Bio-Rad Laboratories Class A in Q4 2021 and held it in 10 quarters.
Paragon Capital Management (Utah)'s Bio-Rad Laboratories Class A position peaked at $1.65M in Q3 2024.
456 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2024.

Based on Paragon Capital Management (Utah)'s 13F filing for Q4 2024, filed 27 Jan 2025.